Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 385.50
Bid: 385.50
Ask: 386.50
Change: -8.50 (-2.16%)
Spread: 1.00 (0.259%)
Open: 386.00
High: 392.00
Low: 385.50
Prev. Close: 394.00
CHG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 Sep 2018 07:00

RNS Number : 6402Z
Chemring Group PLC
04 September 2018
 

FOR IMMEDIATE RELEASE 4 SEPTEMBER 2018

 

CHEMRING GROUP PLC

TRADING UPDATE

 

Chemring Group PLC ("Chemring" or "the Group") today issues an update on trading for the four month period from 1 May to 31 August 2018.

Update on CCM Incident

Following the incident on 10 August at our CCM facility in Salisbury, our injured colleague remains in hospital recovering from his injuries. The Group is committed to supporting him and his family throughout his recovery, along with the family of our colleague who tragically lost his life in the incident.

The investigation into the incident, which occurred in an MTV flare mixing building at the Group's Salisbury site in the UK, is ongoing and the Group is working closely with the regulatory bodies to determine the root cause.

We are also working with the regulatory bodies on the UK CCM site restart plan. The initial steps of this plan will be to complete the shipment of finished goods inventory and initiate a phased restart of non-MTV product lines. The impact on the Group's underlying operating profit in the current financial year is likely to be around the middle of the range of £10m - £20m indicated in the statement made on 13 August.

The Group is still assessing the impact on the 2019 financial year which will be dependent on the site restart plan, as agreed with the regulatory bodies, and expected production rates. The Group is accelerating the transition to more automated MTV production facilities, which will improve operational effectiveness.

The Group has engaged with its insurers, but at this stage it is too early to assess the amount of any claim or the likely timing of any payments. The Group's property damage and business interruption insurance policy has a deductible of £2.5m, an overall policy limit of £60m and a twelve-month indemnity period for business interruption claims.

Countermeasures

The period has seen positive customer demand, resulting in £78m of orders received. The majority of orders were from the US Government for a range of requirements including spectral, infrared and special material decoys, which are manufactured at the Group's US CCM facilities. This provides strong order book coverage for our 2019 financial year.

Sensors

In Sensors, the Group is pleased to announce that it has received a number of significant awards in the period.

In the counter-IED market, Chemring Sensors and Electronic Systems (CSES) has been awarded a $93m, three-year IDIQ to refurbish and refresh the US DOD's fleet of Husky Mounted Detection Systems (HMDS). The initial award under this IDIQ contract is for $20m for delivery in the first year of the contract. CSES has also been awarded a $14m incrementally funded Research and Development contract for the HMDS.

In the biological detection market, CSES has also been awarded an IDIQ contract for the Enhanced Maritime Biological Detection (EMBD) program. The scope of work under this Delivery Order includes Engineering, Manufacturing, and Development (EMD) with options for Low Rate Initial Production (LRIP). The total contract value, including options, is $24m with the initial award under this IDIQ contract being $13.6m, with an initial delivery order of $5m.

In the chemical detection market, CSES has been notified that it was not one of the selected bidders to move to the next stage of the third stream of the Next Generation Chemical Detector (NGCD3) now known as the Multi Phase Chemical Agent Detector (MPCAD). An award decision on the first, and largest, stream of the NGCD program, the Aerosol & Vapor Chemical Agent Detector (AVCAD), is expected shortly.

In the UK, Roke was part of the consortium awarded the contract to provide private sector support to the UK MOD's procurement team in the delivery of the Battlefield Tactical Communication and Information System (BATCIS), the next generation land tactical communications and information system.

Energetics

As expected, in the commoditised pyrotechnic and ammunition market, demand continues to soften. The Group continues to focus on its move away from short-term commodity products to longer-term contracting and partnering agreements in higher margin niche product areas, where the demand for specialist devices and high explosives continues to be robust.

Outlook

Recent contract awards in our Countermeasures and Sensors segments demonstrate both continued customer demand and the progress the Group is making on its roadmap to focus on higher margin, niche market positions where the Group is best placed to generate future value.

With the exception of the impact of the CCM incident, trading across the Group remains in line with the Board's expectations.

 

-ENDS-

 

  

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

 

Andrew Jaques MHP Communications 0203 128 8100

James White

 

Cautionary statement

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,600 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under three strategic product segments: Countermeasures, Sensors, and Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFKNDPOBKDQCK
Date   Source Headline
10th May 20164:20 pmRNSDirector/PDMR Shareholding
5th May 20167:00 amRNSCompletion of Acquisition
3rd May 201610:08 amRNSTotal Voting Rights
27th Apr 20162:13 pmRNSDirectorate Change
25th Apr 20169:52 amRNSDirector/PDMR Shareholding
19th Apr 20167:00 amRNSAPPOINTMENT OF CHAIRMAN-DESIGNATE
6th Apr 20164:15 pmRNSDirector/PDMR Shareholding
4th Apr 20167:00 amRNSContract Update
1st Apr 20169:48 amRNSTotal Voting Rights
24th Mar 201610:36 amRNSHolding(s) in Company
21st Mar 20162:05 pmRNSResult of AGM
21st Mar 201611:00 amRNSAGM Trading Update
8th Mar 20162:36 pmRNSDirector/PDMR Shareholding
7th Mar 20167:00 amRNSAPPOINTMENT OF NON-EXECUTIVE DIRECTOR
1st Mar 20165:26 pmRNSCorrection Re Holding in Company
1st Mar 20161:24 pmRNSTotal Voting Rights
26th Feb 201610:23 amRNSHolding(s) in Company
24th Feb 20168:48 amRNSResult of Rump Placing
23rd Feb 20163:03 pmRNSResults of Rights Issue
23rd Feb 201612:40 pmRNSHolding(s) in Company
19th Feb 20163:13 pmRNSDirector/PDMR Shareholding
9th Feb 20168:07 amRNSAdmission of Nil Paid Rights
8th Feb 201611:52 amRNSResult of EGM
4th Feb 201611:26 amRNSDirector/PDMR Shareholding
4th Feb 201611:25 amRNSDirector/PDMR Shareholding
1st Feb 201611:18 amRNSTotal Voting Rights
27th Jan 20167:00 amRNSDirector/PDMR Shareholding
21st Jan 20163:30 pmRNSPublication of Prospectus
21st Jan 20167:00 amRNS£80.8 million Rights Issue
21st Jan 20167:00 amRNSFinal Results
20th Jan 20164:01 pmRNSDirector/PDMR Shareholding
4th Jan 201610:01 amRNSTotal Voting Rights
21st Dec 201511:19 amRNSBlocklisting Update
21st Dec 201511:17 amRNSBlocklisting Interim Review
1st Dec 20159:57 amRNSTotal Voting Rights
25th Nov 20157:00 amRNSPOST-CLOSE STATEMENT
2nd Nov 201511:21 amRNSHolding(s) in Company
27th Oct 20157:00 amRNSTrading Statement
1st Oct 201511:15 amRNSTotal Voting Rights
29th Sep 20152:25 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSTrading Update
1st Sep 20159:33 amRNSTotal Voting Rights
20th Aug 20153:01 pmRNSHolding(s) in Company
7th Aug 20151:56 pmRNSHolding(s) in Company
3rd Aug 20159:28 amRNSTotal Voting Rights
1st Jul 20152:47 pmRNSTotal Voting Rights
24th Jun 20155:26 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHalf Yearly Report
19th Jun 20158:55 amRNSBlocklisting Update
19th Jun 20157:00 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.